CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $21.79M, above the global median of $16.24M
- FinancialsAltman Z-Score 3.4: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.75%Below 5Y avg (1.00%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
152.6%High
Last Ex-Dividend
May 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.15BCNY319.57M · vs all stocks (USD)
Revenue (TTM)
371.54MCNY55.18M · vs all stocks (USD)
Profit Margin
-0.66%vs Medical Devices peers
Beta
0.2240xvs all stocks
52-Week Change
-45.02%vs all stocks
Market Capitalization
2.15BCNY319.57M · vs all stocks (USD)
Enterprise Value
2.09BCNY311.13M · vs all stocks (USD)
Forward P/E
16.42xvs Medical Devices peers
Price to Sales (TTM)
6.02xvs Medical Devices peers
Price to Book (MRQ)
1.55xvs Medical Devices peers
Enterprise to Revenue
5.64xvs Medical Devices peers
Enterprise to EBITDA
35.65xvs Medical Devices peers
Gross Margin
64.87%vs Medical Devices peers
Profit Margin
-0.66%vs Medical Devices peers
Operating Margin
-2.47%vs Medical Devices peers
Return on Assets (TTM)
0.20%vs Medical Devices peers
Return on Equity (TTM)
-0.41%vs Medical Devices peers
Revenue (TTM)
371.54MCNY55.18M · vs all stocks (USD)
Revenue per Share (TTM)
2.29CNYUpdated Aug 19, 2026Quarterly Revenue Growth
10.30%vs Medical Devices peers
Gross Profit (TTM)
250.44MCNY37.20M · vs all stocks (USD)
EBITDA (TTM)
88.49MCNY13.14M · vs all stocks (USD)
Net Income (TTM)
-2.44MCNY-363.06K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-28.70%vs Medical Devices peers
Operating Cash Flow (TTM)
135.10MCNY20.06M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
146.74MCNY21.79M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.75%vs all stocks
5-Year Average Dividend Yield
1.00%vs all stocks
Payout Ratio
152.59%vs Medical Devices peers
Minority Interest (Equity)
54.02MCNYFY2025 · Dec 31, 2025Revenue
363.83MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
110.76MCNYFY2025 · Dec 31, 2025Gross Profit
253.07MCNYFY2025 · Dec 31, 2025Operating Income
38.50MCNY5.72M · vs all stocks (USD)
Pre-tax Income
-2.88MCNYFY2025 · Dec 31, 2025Income Tax Expense
-2.06MCNYFY2025 · Dec 31, 2025Net Income
-824.40KCNYFY2025 · Dec 31, 2025EBIT
-317.58KCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
88.49MCNYFY2025 · Dec 31, 2025Research & Development
58.46MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
35.21MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.19MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.47MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.56MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0220CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0220CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
163.09MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
163.09MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-824.40KCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.41MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
63.74MCNYFY2025 · Dec 31, 2025Free Cash Flow
-3.45MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
380.90MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-824.40KCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.41MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
59.25MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
900.52KCNYFY2025 · Dec 31, 2025Capital Expenditures
-67.19MCNYFY2025 · Dec 31, 2025Net Acquisitions
-263.93MCNYFY2025 · Dec 31, 2025Purchase of Investments
-633.66MCNYFY2025 · Dec 31, 2025Sale of Investments
673.71MCNYFY2025 · Dec 31, 2025Other Investing Activity
7.09MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-283.99MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
287.14MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-5.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-28.84MCNYFY2025 · Dec 31, 2025Other Financing Charges
-27.41MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
224.91MCNYFY2025 · Dec 31, 2025Shares Outstanding
162.54MSharesUpdated Aug 19, 2026Float Shares
112.71MSharesUpdated Aug 19, 2026% Held by Insiders
33.73%vs all stocks
% Held by Institutions
7.98%vs all stocks
Total Cash (MRQ)
545.32MCNY80.99M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.41CNYUpdated Aug 19, 2026Total Debt (MRQ)
381.72MCNY56.69M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2588xvs Medical Devices peers
Current Ratio (MRQ)
5.38xvs Medical Devices peers
Book Value per Share (MRQ)
8.89CNYUpdated Aug 19, 2026Total Assets
2.06BCNY305.48M · vs all stocks (USD)
Total Current Assets
960.33MCNYFY2025 · Dec 31, 2025Total Liabilities
576.38MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.10BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
380.92MCNYFY2025 · Dec 31, 2025Total Current Liabilities
195.46MCNYFY2025 · Dec 31, 2025Cash
377.36MCNYFY2025 · Dec 31, 2025Cash Equivalents
8.72MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
386.08MCNYFY2025 · Dec 31, 2025Other Short-term Investments
170.57MCNYFY2025 · Dec 31, 2025Accounts Receivable
204.46MCNYFY2025 · Dec 31, 2025Inventory
98.51MCNYFY2025 · Dec 31, 2025Accounts Payable
78.57MCNYFY2025 · Dec 31, 2025Short-term Debt
33.08MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.42MCNYFY2025 · Dec 31, 2025Long-term Debt
367.66MCNYFY2025 · Dec 31, 2025Common Stock (Book)
162.54MCNYFY2025 · Dec 31, 2025Retained Earnings
787.13MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.48BCNY219.87M · vs all stocks (USD)
Treasury Stock
49.02MCNYFY2025 · Dec 31, 202552-Week Low
11.04CNYUpdated Aug 19, 202652-Week High
32.80CNYUpdated Aug 19, 202652-Week Change
-45.02%vs all stocks
Beta
0.2240xvs all stocks
50-Day MA
12.59CNYUpdated Aug 19, 2026200-Day MA
16.65CNYUpdated Aug 19, 2026Avg 10-Day Volume
3.99MSharesUpdated Aug 19, 2026Avg 30-Day Volume
4.18MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.0200CNYUpdated Aug 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.65Profit Margin: -0.01
Financial Health
Altman Z-Score 3.4: safe zoneNotable
Altman Z-Score: 3.40
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $21.79M, above the global median of $16.24MNotable
Levered free cash flow (USD): 21,793,095.27Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shin Poong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Shenzhen Emperor Technology Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineIndustry-Benchmarked ROA and Margin Elevated
Ningbo Color Master Batch Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineIndustry-Benchmarked ROA and Margin Elevated
Aekyung Chemical Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineDown-Close Share With Multi-Year Earnings Decrease